Duke Vaccine Portfolio and Key Programs
Duke University and its affiliated partners operate multiple vaccine programs targeting infectious diseases, oncology, and immune modulation. The Duke Human Vaccine Institute focuses on HIV, influenza, and emerging pathogens, while Duke-NUS Medical School in Singapore collaborates on dengue and COVID-19 research. Duke's vaccine pipeline includes both preclinical and clinical-stage assets, with several candidates supported by federal grants and industry partnerships.
Funding for Duke vaccine work comes from the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and private biotech collaborations. Duke receives competitive grants through the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases. These resources support early-stage discovery, preclinical testing, and first-in-human trials across multiple disease targets.
Clinical Progress and Regulatory Pathways
Several Duke-affiliated vaccine candidates have entered Phase 1 or Phase 2 trials, with data published in peer-reviewed journals and on ClinicalTrials.gov. Duke's HIV vaccine research has advanced to early efficacy studies, while its influenza work targets broadly protective and universal vaccine designs. Duke's COVID-19 research contributed to mRNA and protein subunit platform evaluations during the pandemic response.
Regulatory pathways for Duke vaccine projects follow standard Investigational New Drug and Biologics License Application processes overseen by the U.S. Food and Drug Administration. Duke partners with contract manufacturing organizations and academic centers to support Good Manufacturing Practice production for clinical supplies. Trial results are shared through conferences, publications, and public registries to maintain transparency.
Market Position and Competitive Landscape
Duke vaccines compete in segments dominated by large pharmaceutical companies and specialized biotech firms. Duke's academic model emphasizes fundamental research and platform technologies, with licensing deals and spinout companies translating discoveries into commercial assets. Duke's partnerships with industry aim to accelerate development timelines while maintaining academic rigor and public health focus.
Financially, Duke vaccine programs rely on a mix of government funding, philanthropic support, and industry licensing revenue. The university's innovation ecosystem supports startups and spinouts that commercialize vaccine technologies, with some companies raising venture capital and public market funding. Duke's role in the vaccine ecosystem centers on early-stage science and translational research rather than large-scale manufacturing or direct sales.